August 20, 2024 10:49 AM EDTUpdated 03:34 PM
News Briefing

Kymera seeks to raise $225M; Ad­cen­do, Mul­ti­tude's new ADC deal

ENDPOINTS

Plus, news about Talus Bio­science, Mol­e­culin, Organon and Eli Lil­ly:

Kymera Ther­a­peu­tics aims to raise $225M: The pub­lic of­fer­ing will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

Ther­at­e­ch­nolo­gies' HIV drug to face sup­ply is­sues in 2025 over third-par­ty fa­cil­i­ty shut­down 

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times